Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to $21.1 million.

  • Myriad Genetics' Cash from Operations rose 291428.57% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year increase of 9685.71%. This contributed to the annual value of -$8.7 million for FY2024, which is 9215.51% up from last year.
  • Myriad Genetics' Cash from Operations amounted to $21.1 million in Q3 2025, which was up 291428.57% from -$13.6 million recorded in Q2 2025.
  • Myriad Genetics' 5-year Cash from Operations high stood at $71.8 million for Q1 2021, and its period low was -$54.7 million during Q4 2023.
  • For the 5-year period, Myriad Genetics' Cash from Operations averaged around -$11.4 million, with its median value being -$9.5 million (2021).
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 102954.55% in 2022, then surged by 291428.57% in 2025.
  • Myriad Genetics' Cash from Operations (Quarter) stood at -$9.5 million in 2021, then rose by 23.16% to -$7.3 million in 2022, then tumbled by 649.32% to -$54.7 million in 2023, then skyrocketed by 112.07% to $6.6 million in 2024, then skyrocketed by 219.7% to $21.1 million in 2025.
  • Its Cash from Operations stands at $21.1 million for Q3 2025, versus -$13.6 million for Q2 2025 and -$16.3 million for Q1 2025.